SYN News and Press, Synthetic Biologics Inc. From 11/03/21

Synthetic Biologics (NYSE:SYN): Q3 GAAP EPS of -$0.02 beats by $0.01. Cash and cash equivalents as of September 30, 2021 totaled $72.1 million, an increase of $65.9 million from December 31, 2020. Shares +0.05%. Press Release For further details see: Synthetic Biologics EPS beats by $0....

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 2022...

This week continues putting a focus on small-cap stocks. In particular, we’ve seen many stocks under $5 – or penny stocks – flying high on significant buying momentum. What initially began with a move in “Trump stocks” thanks to Digital World Acquisition C...

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET -- PR Newswire ROCKVILLE, Md. , Oct. 26, 2021 /PRNewswire/ -- Synt...

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 2022 Phase 1 Clinical Program Intended to Support Development of SYN-020 for Multiple Indications ...

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by October 13, 2021; Shareholders of Record May Vote Their Shares by Calling D.F. King &...

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire ROCKVILLE, Md. , Sept. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging ...

Synthetic Biologics, Inc. (SYN) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Vincent Perrone – Director, Corporate Communication Steven Shallcross - Chief Executive and Financial Officer Michael Kaleko - Senior Vice President-Research and Development ...

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable Safety Profile and was Well Tolerated at All Dose Levels; A...

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital Updated Agreement Includes Intellectual Property and Technology for Use of SYN-020 Intestinal Alkaline Phosphatase to Inhibit Liver Fibrosis in Select Diseases, Including No...